The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Keisuke Koeda
No relevant relationships to disclose
Naotoshi Sugimoto
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Junji Tanaka
No relevant relationships to disclose
Masahiro Tsuda
No relevant relationships to disclose
Wataru Okamoto
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Hiroshi Imamura
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Jin Matsuyama
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Norimasa Fukushima
Honoraria - Taiho Pharmaceutical
Yukinori Kurokawa
Honoraria - Taiho Pharmaceutical
Yoshito Komatsu
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Toshimasa Tsujinaka
Honoraria - Taiho Pharmaceutical
Hiroshi Furukawa
No relevant relationships to disclose